Our 12 research and discovery units across China, Denmark, India, the
United Kingdom and the United States are designed to provide the best
scientific environment for the discovery and development of
breakthrough medicines.
Some of our global units are designed to work outside our core R&D organisation to drive concepts and projects that will expand and diversify our pipeline with disruptive medicines.
Across our global research and development network, we are working with both well established and cutting-edge research technology platforms that provide us with the techniques, methods and processes that enhance our treatment accuracy and search.
Below you can get to know our global R&D centres even better.
We were the first global pharmaceutical company to establish a research facility in China. Located in Zhongguancun Life Science Park in Beijing, our research centre in China is a technology centre of excellence and plays a key role in our discovery of novel drug candidates.
In 2019, we launched an open innovation platform in China, INNOVO, to increase partnership with local academic institutions and small biotech companies.
Our centre in Bangalore operates as an integrated part of the project-centric development organisation. The team delivers data management, biostatistics and programming, medical writing, publishing, safety surveillance and medical communication for clinical trials and marketed products.
Måløv is our largest research centre, a site for innovation, idea generation, protein and peptide engineering and formulation, and preclinical testing of medicine candidates across our therapy areas.
The site houses our early drug discovery laboratories, as well as facilities for production upscaling and formulation of lead medicine candidates for clinical testing.
One of our teams at the research centre in Bagsværd is responsible for developing, formulating and manufacturing drug candidates for pre-clinical and clinical testing.
Another team is involved in the collection of adverse events, safety surveillance and event adjudication related to clinical trials, as well as the handling of complaints and product recalls, when needed.
Our centre in Søborg is a project-centric workplace focused on late-stage development across all our therapy areas.
This includes conducting and reporting on clinical trials, registering products, sharing the science, and engaging with health authorities, professional associations and the medical community.
Our research centre in Hillerød is our device innovation hub and a key location for our long-standing industry leadership in pioneering new medical devices and delivery technologies.
With its location in the heart of the University of Oxford medical campus, our research centre and transformational research unit in Oxford brings industry and academia closely together.
The research is focused on discovering novel disruptive therapies for cardiometabolic diseases by combining deep disease understanding of human biology with big data.
Located in the heart of the San Francisco Bay Area, Site Fremont is home to the Cell Therapy R&D GMP Manufacturing facility, which is made up of 90+ cell therapy experts who support projects in pre-clinical and clinical development with high quality and fully compliant stem cell-based products.
Our proximity to world-class academia and a thriving biotech culture in the field of regenerative medicine has allowed us to rapidly develop processes and systems in this innovative field.
Fremont is also the base for designing, engineering and developing the innovative device and delivery systems which will enable our cellular medicines to be delivered to patients. The team at Site Fremont is diverse and energetic, united by a passion to bring life-changing Cell Therapies to patients.
Our team in Boulder comprises the specialized technical operations/chemistry manufacturing and controls (CMC) team for oligonucleotides and RNAi (ribonucleic acid interference) therapeutics, continuing its legacy as the hub for all manufacturing-related activities for GalXC™ and GalXC-Plus™ investigational therapeutics developed from our acquisition of Dicerna Pharmaceuticals, Inc.
With a laboratory completed in 2021 to support analytical and process development, the CMC team works alongside Quality, Regulatory, Technical Operations and RNAi Early Development professionals at our Boulder, Colorado facility and works closely with our teams in Lexington, Massachusetts.
Our Bio Innovation Hub is the headquarters for Global R&D Business Development across all our therapeutic and technology areas. Containing functions in Business Development, Search & Evaluation, and Alliance Management, the Bio Innovation Hub houses the full complement of business functions needed for our external partnering activities. Having a physical presence in the one of the world’s largest life sciences ecosystems is part of our strategy to access the high level of innovation that the US has to offer.
In Cambridge, we work with local companies, venture capitalists, universities, and teaching hospitals to access technologies and therapeutic molecules that allow us to help patients in all our current therapeutic areas. Through a variety of partnership models, we use this innovation to help advance and expand its product portfolio.
Lexington is home to Dicerna, a Novo Nordisk company, which is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease.
Our proprietary GalXC™ and GalXC-Plus™ RNAi technologies have the potential to address conditions that are difficult or impossible to treat with other modalities. Also onsite in Lexington is the Boston Global Development team, which is responsible for leading the clinical advancement of Dicerna’s research pipeline of GalXC™ and GalXC-Plus™ RNAi investigational therapies and select candidates from the broader Novo Nordisk portfolio, targeting both rare and prevalent diseases.
Our research centre located in Watertown is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.
The centre's R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. The centre's team is focused on activities supporting clinical supply chain, drug formulation & manufacturing, and GMP, GCP, auditing in support of Sickle Cell Disease (SCD) programs.
Our research centre in Seattle is focused on digital therapy, data science and artificial intelligence
Furthermore, a dedicated team of device engineers are working with digitalisation and connectivity of medical devices for improved treatment outcome.
